Superintendent Laura Columbia addressed key district updates, including enrollment, air quality concerns at Phillips ...
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. <li /> GLOW2 study design mirrors GLOW1 study, ...
Revenue of $3.3 Million, a 12% Increase Compared to Prior Year ~~ Interim Analysis from MAINSAIL Study Reinforces Safety Profile, Effectiveness and Confirmation of Fusion ~~ Catamaran® ...
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...
The Company is on track to initiate enrollment of DENALI Part 2 in the first half of 2025 ... the caption “Risk Factors” in our most recently filed periodic report on Form 10-K or 10-Q and subsequent ...
Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both ...
"The Nu.Q® Cancer test could support physicians with clinical decision-making following LDCT by identifying the patients at highest risk and whose nodules are more likely to be cancerous, while ...
Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.
Six of baseball’s top players are adding a little extra shine this season. In collaboration with Topps, Fanatics and Nike, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback